Myasthenia gravis and D-penicillamine

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is sometimes associated with myasthenia gravis (MG).
• Uncertainty exists whether D-penicillamine (D-P) treatment for RA causes MG or if the association is coincidental.
• While RA prevalence is high, MG might occur more frequently than expected in RA patients treated with D-P, affecting approximately 1%.

Purpose of the Study:

• To investigate the potential causal link between D-penicillamine (D-P) treatment for rheumatoid arthritis (RA) and the development of myasthenia gravis (MG).
• To explore serological differences in autoantibodies between spontaneous MG and D-P-associated MG to understand the drug's role.

Main Methods:

• Comparative analysis of autoantibody profiles in patients with spontaneous myasthenia gravis (MG) versus those with MG associated with D-penicillamine (D-P) treatment for rheumatoid arthritis (RA).

Main Results:

• Compelling evidence suggests D-penicillamine (D-P) may induce myasthenia gravis (MG) in rheumatoid arthritis (RA) patients.
• Significant differences were observed in autoantibodies between spontaneous MG and D-P-associated MG.
• These serological distinctions suggest D-P influences antigen presentation and/or immunoregulation.

Conclusions:

• D-penicillamine (D-P) is a potential inducer of myasthenia gravis (MG) in rheumatoid arthritis (RA) patients.
• Observed autoantibody differences support a drug-induced mechanism rather than a chance association.
• The findings suggest D-P may alter immune responses, leading to MG development.